二甲双胍缓释片治疗抗精神病药物所致代谢紊乱的临床效果

目的：：研究二甲双胍缓释片对抗精神病药所致代谢紊乱的疗效和安全性。方法：76例应用抗精神病药物所致代谢紊乱的精神分裂症患者随机分为2组，观察组给予二甲双胍缓释片，对照组给予安慰剂，连续观察6个月。于治疗1、3、6个月末监测体质量指数( BMI)、空腹血糖及总胆固醇( TC)、三酰甘油( TG)、低密度脂蛋白( LDL)、高密度脂蛋白( HDL)。阳性和阴性症状量表监测病情变化，副反应量表评定不良反应。结果：观察组患者治疗3和6个月末BMI及治疗1、3和6个月末TC、TG与LDL均明显低于治疗前(P<0.01)，而对照组治疗6个月末TC和LDL均较治疗前、治疗1和3个月末升高(P<0.05~P<0.01)。2组空腹血糖和HDL治疗前后不同时间差异均无统计学意义(P>0.05)。2组患者治疗6个月末BMI、TC、TG、LDL及HDL差异均有统计学意义(P<0.01)；2组治疗前和治疗6个月末阴性症状量表评分差异均无统计学意义(P>0.05)。2组不良反应均轻微。结论：二甲双胍缓释片治疗抗精神病药引起的代谢紊乱安全有效，且不影响患者的精神症状。

The comparative study of metformin extended-release tablets in the treatment of metabolic disorder induced by antipsychotic

Objective:To study the efficacy and safety of metformin extended-release tablets on the metabolic disorder induced by antipsychotic. Methods:Seventy six schizophrenia patients with metabolic disorder induced by antipsychotic were divided into the treated group and control group randomly for 6 months. Monitor body mass index(BMI),fasting blood glucose(FBG) and blood lipid (TC,TG,LDL,HDL) at the end of 1,3 and 6 month. The Positive and Negative Symptom Scale(PANSS) and Treatment Emergent symptoms scale( TESS) were used to measure clinical efficacy. Results:It was decreased that BMI,TC,TG and LDL level at the end of 1 or 3 month in treated group,the differences were statistically significant(P<0. 01),but there was no marked changes in the level of HDL and FBG(P>0. 05). The differences of BMI,FBG,TG and HDL level were not significant in control group(P>0. 05). At the end of 6 month,the differences of BMI,TC,TG,LDL and HDL level were statistically significant between the two groups(P<0. 01). Before and after treatment,the scores of PANSS were not statistically significant between the two groups(P>0. 05). Adverse reactions in the 2 groups were mild. Conclusions:It is effective and safe that metformin extended-release tablet treatment of metabolic disorder induced by antipsychotic,and does not affect the mental symptoms.